
Merck KGaA to Acquire SpringWorks for $3.9B, Expanding Rare Cancer Footprint
Two months after saying it was in advanced talks to acquire SpringWorks Therapeutics, Merck KGaA, Darmstadt, Germany, has announced it agreed to purchase the developer of drugs for severe rare disease and cancer for $3.9 billion. Merck KGaA said the deal …